Medicare Enrolled
Dr. James Orsini, M.D.
Internal Medicine · Belleville, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Orsini from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Orsini?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Orsini
Dr. James Orsini is an internal medicine specialist in Belleville, NJ, with 17 years of NPI registration. Based on federal Medicare data, Dr. Orsini performed 22,507 Medicare services across 2,167 unique beneficiaries.
Between the years covered by Open Payments, Dr. Orsini received a total of $30,545 from 62 pharmaceutical and/or device companies across 433 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Orsini is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 1% volume in NJ
$30,545 industry payments
Medicare Practice Summary
Medicare Utilization ↗22,507
Medicare services
Top 1% in NJ for internal medicine
2,167
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,324 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,850 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,086 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 1,196 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 920 | $1 | $3 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
844 | $8 | $8 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
802 | $8 | $16 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
610 | $68 | $174 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
405 | $107 | $287 |
| Nursing facility visit, high complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves a high level of medical decision making and takes at least 45 minutes. |
367 | $131 | $319 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
345 | $77 | $203 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
314 | $27 | $68 |
| Home visit, established patient, moderate complexity A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service. |
312 | $109 | $263 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
305 | $123 | $313 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
248 | $91 | $219 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
233 | $14 | $36 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
143 | $11 | $32 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
141 | $139 | $378 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
138 | $12 | $29 |
| Home visit, established patient, high complexity A home visit for an established patient involving high-level medical decision making, lasting at least 60 minutes. |
138 | $160 | $398 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
136 | $26 | $66 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
109 | $107 | $290 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
107 | $61 | $152 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
86 | $2 | $5 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
82 | $1 | $2 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
80 | $59 | $149 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
75 | $154 | $378 |
| Home visit, established patient, low complexity A physician visits an existing patient at their residence to provide care involving a low level of medical decision making. The visit lasts at least 30 minutes. |
73 | $63 | $158 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
65 | $157 | $406 |
| Nursing facility discharge management, more than 30 minutes This service involves care coordination and management activities performed by a healthcare professional to prepare a patient for discharge from a nursing facility. It requires more than 30 minutes of time spent on these activities. |
62 | $113 | $271 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
57 | $103 | $272 |
| New patient office visit, complex (60-74 min) | 56 | $183 | $492 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
48 | $31 | $75 |
| Home visit, new patient, high complexity A home visit for a new patient involving high-level medical decision making, lasting at least 75 minutes. |
43 | $174 | $400 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
16 | $51 | $128 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $140 | $386 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.2% high complexity
74.0% medium
21.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$30,545
Total received (2018-2024)
Avg $4,364/year across 7 years
Top 2% in NJ for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
62
Companies
433
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$13,275 (43.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,850 (29.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,420 (27.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$694
2023
$1,256
2022
$3,881
2021
$1,938
2020
$3,482
2019
$12,354
2018
$6,940
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$181
Novartis Pharmaceuticals Corporation
$83
E.R. Squibb & Sons, L.L.C.
$82
ABBVIE INC.
$54
Merck Sharp & Dohme LLC
$43
BeiGene USA, Inc.
$35
Celgene Corporation
$32
Incyte Corporation
$30
Karyopharm Therapeutics Inc.
$19
GlaxoSmithKline, LLC.
$19
Legend Biotech USA Inc.
$19
Janssen Biotech, Inc.
$19
Regeneron Healthcare Solutions, Inc.
$18
PUMA BIOTECHNOLOGY, INC.
$15
SpringWorks Therapeutics, Inc.
$15
Daiichi Sankyo Inc.
$15
SOBI, INC
$15
Top 3 companies account for 49.9% of 2024 payments
All-time payments by company (2018-2024) ›
Seattle Genetics, Inc.
$7,557
Janssen Biotech, Inc.
$3,991
Novartis Pharmaceuticals Corporation
$3,508
Exelixis Inc.
$3,337
AstraZeneca Pharmaceuticals LP
$2,477
Janssen Scientific Affairs, LLC
$2,446
Astellas Pharma US Inc
$2,003
Bayer HealthCare Pharmaceuticals Inc.
$812
E.R. Squibb & Sons, L.L.C.
$441
Incyte Corporation
$423
Merck Sharp & Dohme Corporation
$383
Amgen Inc.
$300
Celgene Corporation
$238
Pharmacyclics LLC, An AbbVie Company
$172
EISAI INC.
$131
Boehringer Ingelheim Pharmaceuticals, Inc.
$130
Karyopharm Therapeutics Inc.
$122
Galvanize Therapeutics, Inc
$120
Foundation Medicine, Inc.
$117
Lilly USA, LLC
$112
Seagen Inc.
$108
Daiichi Sankyo Inc.
$104
SANOFI-AVENTIS U.S. LLC
$99
Janssen Products, LP
$99
Regeneron Healthcare Solutions, Inc.
$95
ASD SPECIALTY HEALTHCARE, LLC
$87
Merck Sharp & Dohme LLC
$86
BeiGene USA, Inc.
$76
CTI BioPharma Corp.
$73
Puma Biotechnology, Inc.
$72
ABBVIE INC.
$54
Kite Pharma, Inc.
$47
PFIZER INC.
$46
Otsuka America Pharmaceutical, Inc.
$44
GENZYME CORPORATION
$44
Eisai Inc.
$44
Global Blood Therapeutics, Inc.
$43
Alexion Pharmaceuticals, Inc.
$38
GlaxoSmithKline, LLC.
$37
Mirati Therapeutics, Inc.
$31
Ipsen Biopharmaceuticals, Inc
$30
Pharmacyclics LLC, an AbbVie Company
$29
Blue Earth Diagnostics Limited
$29
Spectrum Pharmaceuticals Inc.
$28
Teva Pharmaceuticals USA, Inc.
$26
Myovant Sciences Inc.
$24
Rigel Pharmaceuticals, Inc.
$22
Legend Biotech USA Inc.
$19
Takeda Pharmaceuticals U.S.A., Inc.
$18
Genentech USA, Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$15
SpringWorks Therapeutics, Inc.
$15
Epizyme, Inc.,
$15
Blueprint Medicines Corporation
$15
SOBI, INC
$15
Sun Pharmaceutical Industries Inc.
$15
EMD Serono, Inc.
$13
Servier Pharmaceuticals LLC
$13
Gilead Sciences, Inc.
$13
Dendreon Pharmaceuticals LLC
$11
Janssen Pharmaceuticals, Inc
$9
Heron Therapeutics, Inc.
$4
Top 3 companies account for 49.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALIYA SYSTEM · ALUNBRIG · AYVAKIT · Abraxane · Adcetris · Axumin · BENDEKA · BRUKINSA · Balversa · Beleodaq · CALQUENCE · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · ELAHERE · ELIQUIS · ENHERTU · EPKINLY · Enhertu · Erleada · FOUNDATIONONE · Fabhalta · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · IMLYGIC · INJECTAFER · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · MYLOTARG · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OPDIVO · ORGOVYX · OXBRYTA · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Phesgo · REBLOZYL · RETEVMO · RYDAPT · Revlimid · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TIBSOVO · Tavalisse · Trodelvy · Truxima · ULTOMIRIS · VERZENIO · VONJO · VOTRIENT · Vonjo · XARELTO · XPOVIO · XTANDI · Xtandi · YONSA · ZEJULA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (44%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for internal medicine in NJ.
Geographic Context
Internal medicine physicians within 10 mi
10,488
Per 100K population
1227.9
County median income
$76,712
Nearest hospital
CLARA MAASS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Orsini is a mixed practice specialist, with above-average Medicare volume (top 1% in NJ), with speaking/promotional industry engagement in the top 2% of NJ peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Orsini experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Orsini performed 11,850 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Orsini receive payments from pharmaceutical companies?
Yes. Dr. Orsini received a total of $30,545 from 62 companies across 433 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Orsini's costs compare to other internal medicine physicians in Belleville?
Dr. Orsini's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Orsini) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Belleville
Browse internal medicine physicians in Belleville ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in NJ
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in NJ
Which NJ internal medicine physicians receive the most from drug and device companies.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology